Current Challenges in Management of Neurological Disorders (Part-I)

Author(s): Mohammad Amjad Kamal, Mohamed M. Abdel-Daim.

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 7 , 2020

Become EABM
Become Reviewer

[1]
Bakir S, Catalkaya G, Ceylan FD, et al. Role of dietary antioxidants in neurodegenerative diseases: where are we standing? Curr Pharm Des 2020; 26(7): 714-29.
[2]
Gulla S, Lomada D, Anusha L, Reddanna P, Reddy MC. Role of prostaglandins in multiple sclerosis. Curr Pharm Des 2020; 26(7): 730-42.
[3]
Nadeema MS, Al-Abbasia FA, Zamzamia MA, et al. Multiple risk factors: a challenge in the management of Autism. Curr Pharm Des 2020; 26(7): 743-54.
[4]
Singh K, Yadav D, Chouhan P, Mishra M, Jin JO. Novel therapeutics for the treatment of Alzheimer’s and Parkinson’s disorders. Curr Pharm Des 2020; 26(7): 755-63.
[5]
Tran PHL, Duan W, Lee B-J, Tran TTD. Current perspectives on delivery systems using extracellular vesicles in neurological disease. Curr Pharm Des 2020; 26(7): 764-71.
[6]
Rahman MA, Rahman MR, Zaman T, et al. The emerging potential of naturally occurring autophagy modulators against neurodegeneration. Curr Pharm Des 2020; 26(7): 772-9.
[7]
Wang L, Liu S, Xu J, et al. A traditional Chinese medicine, YXQN, reduces amyloid-induced cytotoxicity by inhibiting Aβ42 aggregation and fibril formation. Curr Pharm Des 2020; 26(7): 780-9.
[8]
Jamal QMS, Siddiqui MU, Alharbi AH, et al. A computational study of natural compounds from Bacopa monnieri in the treatment of Alzheimer’s disease. Curr Pharm Des 2020; 26(7): 790-800.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 7
Year: 2020
Page: [711 - 713]
Pages: 3
DOI: 10.2174/138161282607200309122739

Article Metrics

PDF: 16
HTML: 4
EPUB: 1
PRC: 1